Talk:EudraGMP

This article is part of a series of articles trying to provide additional information on several aspects of clinical development (trying to fill some gaps). Pvosta 11:21, 19 October 2006 (UTC)

This article is very informative about EudraGMP and provides the public with knowledge that they otherwise would not have had an opportunity to obtain. It is written very clearly and concisely so that someone without any knowledge in pharmaceutical sciences would be able to understand it. I really like the use of bulleted statements, because they are easier to read than full sentences and make the page look much less dense and daunting.Meganh1111 (talk) 00:25, 18 November 2013 (UTC)

I agree with Meganh1111 (talk). Prior to your input, there was not much information here on EudraGMP, but I have a much better understanding now, and you've worded everything quite clearly. XFhqwhgadsX2 (talk) 23:25, 20 November 2013 (UTC)

This is a well-written and informative article, but you could expand it a little further with a few more references.

External links modified
Hello fellow Wikipedians,

I have just modified one external link on EudraGMP. Please take a moment to review my edit. If you have any questions, or need the bot to ignore the links, or the page altogether, please visit this simple FaQ for additional information. I made the following changes:
 * Added archive https://web.archive.org/web/20061017232059/http://ec.europa.eu/idabc/en/chapter/565 to http://ec.europa.eu/idabc/en/chapter/565

When you have finished reviewing my changes, you may follow the instructions on the template below to fix any issues with the URLs.

Cheers.— InternetArchiveBot  (Report bug) 10:41, 24 September 2017 (UTC)